Abivax (ABVX) to Release Earnings on Monday

Key Points

• Abivax is set to announce its Q2 2025 earnings on August 11th, with expectations of a loss of ($0.92) per share and revenue of $1.19 million.
• Shares of ABVX opened at $70.68, with a 1-year high of $75.51 and a low of $4.77, indicating significant volatility in stock performance.
• Several institutional investors, including Millennium Management and Woodline Partners, have recently increased their positions in Abivax, showing growing confidence among investors.

Abivax (NASDAQ:ABVX - Get Free Report) is expected to post its Q2 2025 quarterly earnings results after the market closes on Monday, August 11th. Analysts expect Abivax to post earnings of ($0.92) per share and revenue of $1.19 million for the quarter.

Abivax Trading Down 1.8%

Shares of ABVX stock opened at $70.68 on Monday. The stock's fifty day simple moving average is $17.46 and its 200-day simple moving average is $10.36. The company has a current ratio of 1.25, a quick ratio of 1.25 and a debt-to-equity ratio of 1.29. Abivax has a 1-year low of $4.77 and a 1-year high of $75.51.

Institutional Investors Weigh In On Abivax

Several institutional investors have recently made changes to their positions in ABVX. Millennium Management LLC raised its position in Abivax by 6.0% during the first quarter. Millennium Management LLC now owns 987,414 shares of the company's stock valued at $6,171,000 after purchasing an additional 56,235 shares in the last quarter. Woodline Partners LP boosted its position in shares of Abivax by 319.5% during the 1st quarter. Woodline Partners LP now owns 201,924 shares of the company's stock worth $1,262,000 after purchasing an additional 153,788 shares in the last quarter. Cubist Systematic Strategies LLC boosted its position in shares of Abivax by 34.3% during the 1st quarter. Cubist Systematic Strategies LLC now owns 10,152 shares of the company's stock worth $63,000 after purchasing an additional 2,595 shares in the last quarter. Finally, Bank of America Corp DE raised its holdings in shares of Abivax by 56.1% in the 4th quarter. Bank of America Corp DE now owns 5,536 shares of the company's stock worth $41,000 after acquiring an additional 1,990 shares during the last quarter. 47.91% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on ABVX. Morgan Stanley upgraded Abivax from an "equal weight" rating to an "overweight" rating and set a $71.00 target price for the company in a research note on Wednesday, July 23rd. Piper Sandler increased their target price on Abivax from $70.00 to $112.00 and gave the company an "overweight" rating in a research note on Tuesday, July 29th. Lifesci Capital raised their price objective on Abivax from $45.00 to $101.00 and gave the stock an "outperform" rating in a research report on Wednesday, July 23rd. JMP Securities raised their price objective on Abivax from $33.00 to $95.00 and gave the stock a "market outperform" rating in a research report on Wednesday, July 23rd. Finally, Citigroup reissued a "market outperform" rating on shares of Abivax in a report on Friday, July 18th. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, Abivax currently has an average rating of "Buy" and a consensus price target of $92.33.

Abivax Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.